Introduction
It is a major clinical and public health problem that a variable proportion of individuals with T2D remains undiagnosed and untreated before developing diabetes complications. 1 Many patients with T2D thus present with complications already at time of diagnosis, 1 as the various pathophysiological abnormalities associated with T2D, such as hyperglycemia, dyslipidemia, and hypertension may have existed for several years. 2, 3 Recent data on the prevalence of diabetes-related complications at time of diagnosis are scarce.
Many studies that examined this issue are 10-20 years old, and generally showed high prevalences of complications, 4 e.g., a ~ 36% prevalence of retinopathy in the UKPDS study. 4 Diabetes case-finding has been increasing in populations-at-risk, 5 likely leading to earlier diabetes diagnoses and possibly a lower prevalence of complications at onset. 6, 7 For example, Thomsen et al. 6 found that the median baseline hemoglobin A1c (HbA1c) measurement before initial glucose-lowering treatment in Denmark declined from 8.9% in 2000-2003 to 7.0% in 2010-2012, suggesting earlier diagnosis and therapy.
It is not well understood at present whether pathogenic processes leading to micro-and macrovascular T2D complications differ. 8 Hyperglycemia per se seems to be an important risk factor for microvascular outcomes but less so for macrovascular outcomes, for which traditional cardiovascular risk factors may play a greater role. 4, 9 Moreover, several recent randomized clinical trials (RCTs) [10] [11] [12] [13] have found that newer diabetes drugs exert a CVD protective effect beyond their glucose-lowering effect. 9 In this context, we hypothesized that clinical characteristics at baseline may differ between T2D patients presenting with micro-and macrovascular complications, with dysglycemia-related factors being more important for microvascular complications and metabolic syndrome-related factors more important for macrovascular complications. In the present study, we examined the prevalence of micro-and macrovascular complications and associated characteristics among newly diagnosed T2D patients in a large prospective Danish cohort.
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Materials and methods
Study population
We conducted this cross-sectional study using information from the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project, which includes a nationwide cohort of newly or recently diagnosed type 2 diabetes mellitus (T2D) patients enrolled from general practitioners' (GPs) offices and hospital specialist outpatient clinics in Denmark since November 2010. 14 The implementation and logistics of the DD2 project, patient enrollment, and the DD2 biobank 15 have been described in detail previously. 16 
Micro-and macrovascular complications
For each cohort member, we assessed presence or absence of diabetes complications as recorded in the DNPR between 10 years before and up till 6 months after the DD2 enrolment date. The 6 months after
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period was included to allow for investigation and diagnosis of prevalent diabetes complications shortly after diabetes diagnosis. We categorized diabetes complications as: (1) Table A1 for diagnosis and procedure codes). Denmark, patients volunteer to participate in the DD2 project. Their willingness to participate is documented by a signed written informed consent document.
Associated patient characteristics
Statistical analysis
We characterized patients according to factors as described above. Prevalence of microvascular, macrovascular, and both micro-and macrovascular complications at baseline was calculated as proportions (percentages) of all DD2 cohort members. We calculated prevalence ratios (PRs) with 95% confidence intervals (CIs) of the different complications associated with presence of each factor using log-binomial and Poisson regression. 20 The exact pathophysiological pathways between the different dysglycemia-related and metabolic syndrome-related factors are incompletely understood and several factors may act as clusters in the same causal pathway. 21 We therefore only adjusted our estimates for age and gender in the main analysis (aPRs) to assess whether associations were independent of these two factors. 20 Because obesity and in particular abdominal obesity is thought to be a fundamental factor preceding a number of other metabolic risk factors in many individuals; we did a supplementary analysis in which we also adjusted all associations for WHR category as a marker of abdominal obesity.
Although the DD2 project aims to enroll newly or recently diagnosed T2D patients, we conducted a sensitivity analysis to maximize the probability of T2D being a newly detected diagnosis: in this analysis, we included only T2D patients who had no earlier glucose-lowering treatment, hospital diagnosis of T2D, or registration in the DDDA quality-of-care database recorded more than 1 year prior to DD2 enrollment.
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In addition, we calculated aPRs separately for individual complications, i.e. retinopathy, neuropathy, nephropathy, ischemic heart disease, atherosclerotic cerebrovascular disease, and atherosclerotic peripheral vascular disease.
All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina).
Results
Prevalence data
Among the 6958 patients with T2D, 35% (n=2456) had diabetes complications around enrolment in the DD2 cohort. Of these patients, 12% (n=828) had microvascular complications only, 17% (n=1186) had macrovascular complications only, and 6% (n = 442) had both micro-and macrovascular complications ( 
Characteristics associated with micro-and macrovascular complications
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Characteristics associated with individual complications
Characteristics associated with individual micro-and macrovascular complications are presented in 
Discussion
Our findings from the nationwide DD2 study cohort show that one-third of newly or recently diagnosed T2D patients have hospital-diagnosed micro-and macrovascular complications already around time of diagnosis. Of concern, this suggests that many patients have their T2D diagnosed on the basis of already 
Strengths and limitations
The main strength of this large cross-sectional study is its comprehensive and detailed assessment of lifestyle and clinical factors based on the DD2 database, DD2 biobank, and linkage with population-based
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ACCEPTED MANUSCRIPT health registries. These resources provide close to 100% completeness for demographic, clinical characteristics and prescription data for the newly diagnosed T2D patients in our study. 17 Our study also has important limitations. Firstly, the cross-sectional design of our study leads to intrinsic uncertainty as to whether given diabetes complications preceded or followed the diagnosis of T2D and some of the patient characteristics, making it difficult to draw firm conclusions about the direction of exposure-outcome associations. Secondly, although the DD2 project aims to enroll newly diagnosed T2D patients, some may have been diagnosed with diabetes several years before enrolment, 22 which may have led to an overestimation of the true complication prevalence at diabetes debut. Thirdly, the DD2 cohort may represent patients whose newly diagnosed T2D is more severe than average in Denmark, as initial enrolment took place in hospital specialist outpatient clinics in about half of the cases. 17 This may represent an example of Berksonian-like bias if an undiagnosed diabetic complication leads patients to seek medical attention in secondary health care, thus causing T2D to be diagnosed and the patient to be enrolled in the DD2, with a possible overestimation of the average complication prevalence in early T2D. However, since 2013, the number of patients recruited by GPs has increased rapidly and by 2016 characteristics of the cohort appear to be representative of all newly diagnosed T2D patients in Denmark. 6 Fourth, assessment of complications exclusively through hospital contact diagnoses leads to likely underestimation, especially for microvascular complications, but probably less so for macrovascular complications. Thus, when comparing with results from RCTs, it must be kept in mind that our complication data are not derived from a structured evaluation following briefly after diagnosis, leading to a likely underestimation.
Comparison with previous literature
The lower prevalence of individual diabetes complications in our cohort compared with older studies may originate in earlier and more complete detection of T2D cases in recent years, or be due to improvements over time in clinical management 23 which seem to have decreased the gap in life expectancy for persons with diabetes versus the general population. 24 The UKPDS study, 4 which enrolled patients with newly
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diagnosed diabetes referred by GPs, reported a 36% prevalence of retinopathy and an 11.5% prevalence of neuropathy. Our observed prevalence of 12.8% with retinopathy and 3.8% with neuropathy was more comparable with that reported among screen-detected T2D patients 5 years after diagnosis in the ADDITION study 25 (11% and 5.5%, respectively). Compared to our findings, the ADDITION study reported a much higher prevalence of nephropathy (23% vs. 3.4% in our study), likely because we were only able to assess nephropathy through manifest hospital diagnoses and not by albuminuria 25 
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patients reduces the risk of microvascular complications by 10% -28%. Of note, high triglyceride levels, but not HDL cholesterol levels, were also associated with microvascular complications, and absence of lipid-lowering drug use was associated with microvascular complications at diagnosis. In analyses of individual complications, high triglyceride and low HDL cholesterol levels were clearly associated with nephropathy, consistent with a large case-control study 35 that reported strong associations between diabetic kidney disease, high triglyceride levels, and low HDL cholesterol levels. We did not find an association between retinopathy or neuropathy and high triglyceride or low HDL cholesterol levels, as other studies have reported. 36,37
Conclusion
In conclusion, almost one-third of newly or recently diagnosed T2D patients in the DD2 cohort presented with a likely diabetic complication around disease onset. Our findings suggest that different phenotypical risk profiles exist for microvascular versus macrovascular complications, pointing to different pathophysiological mechanisms and a possible need to individualize preventive treatment strategies.
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